menu
    • menu
    [{"orgOrder":0,"company":"Myrtelle","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Licensing Agreement","leadProduct":"rAAV-Olig001-ASPA","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intracerebroventricular","sponsorNew":"Myrtelle \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Pfizer"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Forge Biologics","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Partnership","leadProduct":"AAV-based TMPRSS3 Gene Therapy","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"IND Enabling","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Otolaryngology","amount2New":0,"dosageForm":"","sponsorNew":"Myrtelle \/ Myrtelle","highestDevelopmentStatusID":"5","companyTruncated":"Myrtelle \/ Myrtelle"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"rAAV-Olig001-ASPA","moa":"Aspartoacylase gene","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Not Applicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"rAAV-Olig001-ASPA","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Not Applicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"MYR-101","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Myrtelle \/ Not Applicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"Levetiracetam","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myrtelle \/ Not Applicable"},{"orgOrder":0,"company":"Myrtelle","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"MYR-101","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Myrtelle","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Myrtelle \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Myrtelle \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Myrtelle

    Menu

    Myrtelle

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MYR-101,Levetiracetam,Prednisone

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Myrtelle Reports NAA Reduction in Phase 1/2 Gene Therapy Trial For Canavan Disease

                            Details : MYR-101 (rAAV-Olig001-ASPA) is a gene therapy candidate, which is intended to restore ASPA function and brain development in patients with Canavan Disease.

                            Brand Name : MYR-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 10, 2024

                            Lead Product(s) : MYR-101,Levetiracetam,Prednisone

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MYR-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Myrtelle’s Gene Therapy Lowers Key Biomarker in Canavan Disease

                            Details : MYR-101 (rAAV-Olig001-ASPA) is a gene therapy candidate, which is intended to restore ASPA function and brain development in patients with Canavan Disease.

                            Brand Name : MYR-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 01, 2024

                            Lead Product(s) : MYR-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : MYR-101

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Myrtelle: FDA Selects rAAV-Olig001-ASPA for Canavan START Program

                            Details : MYR-101 (rAAV-Olig001-ASPA) is a gene therapy candidate, which is intended to restore ASPA function and brain development in patients with Canavan Disease.

                            Brand Name : MYR-101

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 05, 2024

                            Lead Product(s) : MYR-101

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAAV-Olig001-ASPA

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Myrtelle Announces Positive Interim Data in Phase 1/2 Clinical Trial of Its Proprietary Investigational Gene T...

                            Details : rAAV-Olig001-ASPA is the first gene therapy designed to target the oligodendrocytes, which are critical for myelination and nerve function. Therepy reduces N-Acetylaspartate concentration, allowing myelination to occur. It is currently being investigated...

                            Brand Name : rAAV-Olig001-ASPA

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 09, 2023

                            Lead Product(s) : rAAV-Olig001-ASPA

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAAV-Olig001-ASPA

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Myrtelle Completes Dosing of 8 Patients with Canavan Disease in Its Phase 1/2 Clinical Trial of the Investigat...

                            Details : rAAV-Olig001-ASPA is a novel vector from a class of recombinant AAVs that selectively target oligodendrocytes–the cells in the brain responsible for producing myelin, the insulating material that enables proper function of neurons and makes up the brai...

                            Brand Name : rAAV-Olig001-ASPA

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 04, 2022

                            Lead Product(s) : rAAV-Olig001-ASPA

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AAV-based TMPRSS3 Gene Therapy

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : IND Enabling

                            Recipient : Forge Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Myrtelle and Forge Biologics Announce Viral Vector and Plasmid DNA cGMP Manufacturing Partnership

                            Details : Forge will provide research-grade and GMP-Pathway plasmid manufacturing services as well as cGMP adeno-associated viral (AAV) process development and scale-up manufacturing services for Myrtelle’s program, Myr-201 (gene therapy delivery of a therapeuti...

                            Brand Name : Myr-201

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            October 03, 2022

                            Lead Product(s) : AAV-based TMPRSS3 Gene Therapy

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : IND Enabling

                            Recipient : Forge Biologics

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Myrtelle

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : rAAV-Olig001-ASPA

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Myrtelle Announces Exclusive Worldwide Gene Therapy Licensing Agreement for Canavan Disease

                            Details : Following the licensing agreement, Myrtelle is now conducting a first-in-human Phase I/II clinical study for CD under an open U.S. Investigational New Drug (IND) AVASPA.

                            Brand Name : AVASPA

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            December 14, 2021

                            Lead Product(s) : rAAV-Olig001-ASPA

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Pfizer Inc

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth